Leukemia Therapeutics Market to hit USD 59.4 Bn by 2035

The global Leukemia Therapeutics Market was valued at USD 25.8 billion in 2025 and is projected to reach USD 59.4 billion by 2035, growing at a CAGR of 8.7%. North America led the market with a 43.1% share in 2025, while the U.S. market reached USD 7.6 billion and is expected to grow at a 7.8% CAGR, ssupported by rising diagnosis rates, wider access to advanced therapies, and strong oncology research investment.

Key Takeaways

• Targeted therapy accounted for 40.3% share in the leukemia therapeutics market, supported by higher treatment precision, improved patient outcomes, and wider use of mutation-specific therapies.

• Chronic lymphocytic leukemia led by leukemia type with 31.1% share, driven by higher disease prevalence among older adults and increasing use of advanced treatment regimens.

• Small-molecule drugs accounted for 36.8% share, supported by strong adoption of oral and targeted treatment options across leukemia care.

• Injectable mode held 67.2% share by route of administration, driven by the continued use of chemotherapy, monoclonal antibodies, immunotherapies, and hospital-based treatments.

• The geriatric age group, 65 years and above, accounted for 58.6% share, as leukemia incidence remains higher among older patients.

• North America held 43.10% share of the leukemia therapeutics market, supported by advanced healthcare infrastructure, strong oncology drug access, and high treatment adoption.

• The U.S. leukemia therapeutics market was valued at USD 7.6 billion and is projected to grow at a CAGR of 7.8%.

Report Overview

The leukemia therapeutics market covers medicines and treatment methods used to manage acute and chronic forms of leukemia, including acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia. The market includes chemotherapy, targeted therapy, immunotherapy, CAR-T cell therapy, stem cell transplantation, and newer precision medicines that act on specific genetic changes in cancer cells.

The growth of the leukemia therapeutics market can be attributed to the shift from conventional chemotherapy toward targeted and immune-based therapies. Tyrosine kinase inhibitors, monoclonal antibodies, bispecific antibodies, CAR-T cell therapies, and menin inhibitors are improving treatment options for patients with specific disease profiles. This trend is especially important in relapsed or refractory leukemia, where standard treatment options are limited and survival outcomes remain difficult.

Demand for leukemia therapeutics is rising due to the high disease burden across both adult and pediatric populations. In the United States, chronic lymphocytic leukemia is expected to record about 22,760 new cases and 4,350 deaths in 2026, making it one of the most common leukemia types. Acute lymphocytic leukemia is expected to account for about 6,250 new cases and 1,600 deaths in the United States in 2026, with the highest risk seen in children younger than five years.

Segment Highlights

By Treatment Type: Targeted Therapy

Targeted therapy accounted for 40.3% share in the Leukemia Therapeutics Market, supported by rising use of precision medicines that act on specific cancer-related pathways. These therapies are widely used in chronic lymphocytic leukemia, chronic myeloid leukemia, and selected acute leukemia cases where genetic markers and disease biology guide treatment decisions.

The segment is gaining importance because targeted drugs can offer more focused treatment than conventional chemotherapy in several leukemia types. The American Cancer Society notes that targeted therapy is commonly used for chronic lymphocytic leukemia and includes medicines that act on proteins involved in cancer cell growth and survival.

By Leukemia Type: Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia led the Leukemia Therapeutics Market with a 31.1% share. This leadership is supported by the high treatment need among older adults, wider use of targeted medicines, and ongoing treatment advances for relapsed and refractory disease.

CLL remains a major leukemia category in the U.S., with the American Cancer Society estimating about 22,760 new CLL cases and 4,350 deaths in 2026. CLL accounts for about 1 in 3 new leukemia cases in the U.S., and the average age at diagnosis is around 70 years, which supports strong demand for therapies suited to older patients.

By Therapeutic Modality: Small-Molecule Drugs

Small-molecule drugs accounted for 36.8% share in the Leukemia Therapeutics Market, supported by the strong use of oral targeted medicines such as kinase inhibitors, BCL-2 inhibitors, and other pathway-focused treatments. These drugs are important because they can enter cells and act on specific molecular targets involved in leukemia progression.

The segment is also supported by continued regulatory activity in targeted leukemia medicines. In December 2025, the FDA granted traditional approval to pirtobrutinib for adults with relapsed or refractory CLL or small lymphocytic lymphoma after prior treatment with a covalent BTK inhibitor.

By Route of Administration: Injectable Mode

Injectable mode held 67.2% share in the Leukemia Therapeutics Market, supported by the continued use of injectable chemotherapy, monoclonal antibodies, immunotherapy, and hospital-based infusion treatments. This route remains important because many leukemia therapies require controlled administration, dose monitoring, and clinical supervision.

Injectable treatments are especially relevant in acute leukemia care, combination regimens, and cases where patients require intensive therapy. Mayo Clinic notes that many chemotherapy medicines are given through a vein, while some leukemia treatments are available in pill form, showing why injectable care remains central to leukemia treatment pathways.

By Age Group: Geriatric (65+ Years)

The geriatric (65+ years) group accounted for 58.6% share, mainly because leukemia risk increases with age for several major disease types. Older patients often need treatment plans that balance disease control, tolerability, comorbidities, and quality of life.

This segment is strongly linked to chronic leukemia burden. The American Cancer Society states that CLL mainly affects older adults, with an average diagnosis age of around 70 years, while CML has an average diagnosis age of around 66 years. These age patterns support the high share of geriatric patients in leukemia therapeutics demand.

By Regional Analysis: North America

North America held 43.10% share in the Leukemia Therapeutics Market, supported by advanced cancer care infrastructure, early access to new therapies, strong clinical research activity, and high treatment adoption. The region also benefits from established oncology networks, reimbursement systems, and specialist-led treatment pathways.

The U.S. market was valued at USD 7.6 billion and is projected to grow at a CAGR of 7.8%. Growth is supported by rising use of targeted therapy, increasing survival needs, and the large diagnosed patient base across CLL, AML, ALL, and CML. The American Cancer Society estimated 6,250 new ALL cases and 9,650 new CML cases in the U.S. for 2026, adding to the country’s overall leukemia treatment demand.

Market Segmentation

By Treatment Type

• Chemotherapy

• Immunotherapy

• Targeted Therapy

• CAR-T Cell Therapy

• Gene Therapy

• Stem Cell Transplantation

• Other Treatment Types

By Leukemia Type

• Acute Lymphoblastic Leukemia

• Acute Myeloid Leukemia

• Chronic Lymphocytic Leukemia

• Chronic Myeloid Leukemia

• Other Leukemia Types

By Therapy Modality

• Small-Molecule Drugs

• Monoclonal Antibodies

• CAR-T Cell Therapies

• Gene Therapies

• Bispecific Antibodies

• RNA-based Therapies

• Other Modalities

By Route of Administration

• Oral

• Intravenous

• Subcutaneous

• Other Routes

By Age Group

• Pediatric (<14 yrs)

• Adult (15–64 yrs)

• Geriatric (65+ yrs)

By Region

• North America

• Europe

• Asia Pacific

• Latin America

Market Dynamics

Drivers Impact Analysis

Restraints Impact Analysis

Opportunities Impact Analysis

Challenges Impact Analysis

Recent Developments

• May 2026 – Taiho Oncology received U.S. FDA approval for Inqovi plus venetoclax for newly diagnosed acute myeloid leukemia, or AML, in adults aged 75 years and above or patients not eligible for intensive chemotherapy. The approval was based on the ASTX727-07 trial with 101 patients. This supports demand for oral AML regimens that reduce frequent clinic visits.

• May 2026 – AbbVie received U.S. FDA approval for pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, a rare aggressive blood cancer. In trials, 23 of 33 untreated patients and 8 of 51 relapsed or refractory patients achieved full remission. The approval strengthens AbbVie’s hematology position and expands treatment options for patients with limited alternatives.

• March 2026 – Merck agreed to acquire Terns Pharmaceuticals for about USD 6.7 billion. The deal adds TERN-701, an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor for chronic myeloid leukemia, or CML. The transaction shows strong M&A interest in targeted hematology pipelines and next-generation leukemia therapies.